冠心舒通胶囊联合瑞舒伐他汀对支架术后老年冠心病患者长期预后的影响

目的:观察冠心舒通胶囊联合瑞舒伐他汀对支架术后老年冠心病患者长期预后的作用及对其血小板功能、血清白细胞介素-6 (IL-6)、肿瘤坏死因子-α(TNF-α)的影响。方法:将123例支架术后老年冠心病患者按照随机数字表法分为对照组和研究组,对照组患者给予瑞舒伐他汀治疗,研究组在对照组的基础上给予冠心舒通胶囊治疗。观察2组患者的临床疗效;比较2组患者治疗前后血小板膜P选择素(CD62P)、溶酶体相关膜蛋白3 (CD63)、血小板膜糖蛋白Ⅱb/Ⅲa复合物(GPⅡb/Ⅲa)水平及血清IL-6、TNF-α水平变化;统计2组术后心血管不良事件发生情况与靶血管重建情况。结果:研究组总有效率为90.16%,高于对照组的74.19%(P<0.05)。2组治疗后CD62P、CD63与GPⅡb/Ⅲa水平均低于治疗前(P<0.05),且研究组低于对照组(P<0.05);2组治疗后血清IL-6、TNF-α水平均低于治疗前(P<0.05),且研究组低于对照组(P<0.05);研究组患者心血管不良事件与靶血管重建发生率均低于对照组(P<0.05)。结论:冠心舒通胶囊联合瑞舒伐他汀治疗可有效改善支架术后老年冠心病患者预后及血小板功能,降低血清IL-6、TNF-α水平。

Effect of Guanxin Shutong Capsules Combined with Rosuvastatin on Long-Term Prognosis of Senile Patients with Coronary Heart Disease After Stenting

Objective: To observe the effect of Guanxin Shutong capsules combined with rosuvastatin on long-term prognosis of senile patients with coronary heart disease after stenting and its effect on platelet function, as well as interleukin-6(IL-6) and tumor necrosis factor-α(TNF-α) in serum. Methods: A total of 123 cases of senile patients with coronary heart disease after stenting were divided into the control group and the study group according to the random number table method. The control group was given rosuvastatin,and the study group was additionally treated with Guanxin Shutong capsules based on the treatment of the control group. The clinical effect in the two groups was observed. Before and after treatment,the changes in the levels of platelet membrane P-selectin(CD62 P),lysosome associated membrane protein 3(CD63) and platelet membrane glycoproteins Ⅱ b/Ⅲ a(GPⅡb/Ⅲa) as well as IL-6 and TNF-α in serum in the two groups were compared. After surgery, the incidences of postoperative cardiovascular adverse events and the reconstruction of target vessels in the two groups were analyzed. Results:The total effective rate was 90.16% in the study group,higher than that of 74.19% in the control group(P<0.05). After treatment,the levels of CD62 P,CD63 and GPⅡb/Ⅲa were lower than those before treatment(P<0.05),and the levels in the study group were lower than those in the control group(P<0.05);the levels of IL-6 and TNF-α in serum in the two groups were lower than those before treatment(P<0.05),and the levels in the study group were lower than those in the control group(P<0.05);the incidences of cardiovascular adverse events and target vessel revascularization in the study group were lower than those in the control group(P<0.05). Conclusion:The therapy of Guanxin Shutong capsules combined with rosuvastatin for senile patients with coronary heart disease after stenting can effectively improve their prognosis and platelet function,and reduce the levels of IL-6 and TNF-α in serum.